SCHEDULE: Perceptive Advisors Discloses 10.1% Stake in Freenome

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported beneficial ownership of 10.1% of Freenome, Inc.'s common stock as of July 20, 2026.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively disclosed beneficial ownership of 10,871,847 shares of Freenome, Inc. common stock.
• This holding represents 10.1% of the outstanding common stock, based on 107,446,814 shares outstanding as of July 20, 2026.
• The filing indicates that Perceptive Life Sciences Master Fund, Ltd. directly holds the shares.
• Perceptive Advisors LLC acts as the investment manager for the Master Fund, and Joseph Edelman, as the managing member of Perceptive Advisors, may be deemed to beneficially own these shares.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of Freenome, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it indicates significant investor interest from Perceptive Advisors, it lacks operational or financial details to assess the company's performance or future prospects.

Positives

• Significant stake held by a known investment manager (Perceptive Advisors) suggests confidence in Freenome's long-term prospects.
• The 10.1% ownership indicates a substantial investment, potentially providing stability and strategic support to Freenome.

Negatives

• The filing does not contain financial performance data or operational updates, limiting the assessment of current business health.
• No specific details are provided regarding the strategy behind this investment or future intentions beyond the certification of non-control purpose.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific business risks or operational challenges faced by Freenome.
• The concentration of ownership by a single entity could potentially lead to conflicts of interest or influence over corporate decisions, although the filing certifies against this intent.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Freenome's future performance. It solely reports on ownership stakes.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in this Schedule 13G filing by Perceptive Advisors, is common in the biotechnology and healthcare sectors. Such filings often signal a belief in the company's technology or market potential, especially for companies like Freenome operating in the advanced diagnostics space.

Stakeholder Impact

• Shareholders: The increased institutional ownership may signal confidence, potentially influencing share price, but the lack of operational details limits immediate impact assessment.
• Management: The significant stake by Perceptive Advisors could lead to increased engagement or influence on strategic decisions, though the filing disclaims control intent.

Next Steps

• Monitor future filings from Perceptive Advisors for any changes in their stake or disclosed intentions.
• Observe Freenome's operational and financial performance for insights into the value of this investment.

Key Dates

Keywords

Freenome, Perceptive Advisors, Schedule 13G, Beneficial Ownership, Healthcare, Biotechnology, Investment Management, Life Sciences